| # | Drug | Count |
|---|---|---|
| 0 | ADALIMUMAB | 281 |
| 1 | SECUKINUMAB | 247 |
| 2 | RISANKIZUMAB-RZAA | 200 |
| 3 | OFATUMUMAB | 186 |
| 4 | ABATACEPT | 183 |
| 5 | VEDOLIZUMAB | 162 |
| 6 | ONABOTULINUMTOXINA | 161 |
| 7 | INSULIN GLARGINE | 139 |
| 8 | TOCILIZUMAB | 131 |
| 9 | GUSELKUMAB | 121 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | AVACINCAPTAD PEGOL | 16 | 0.0455 |
| 1 | TISOTUMAB VEDOTIN | 22 | 0.0227 |
| 2 | CRIZANLIZUMAB | 22 | 0.0157 |
| 3 | ANDEXANET ALFA | 10 | 0.0141 |
| 4 | ROPEGINTERFERON ALFA-2B | 21 | 0.0113 |
| 5 | INFLIXIMAB-DYYB | 34 | 0.0099 |
| 6 | BRENTUXIMAB VEDOTIN | 94 | 0.0090 |
| 7 | CASIMERSEN | 8 | 0.0081 |
| 8 | TESTOSTERONE ENANTHATE | 11 | 0.0067 |
| 9 | ETEPLIRSEN | 16 | 0.0066 |
| # | Drug class | Count |
|---|---|---|
| 0 | Interleukin-23 Antagonist [EPC] | 370 |
| 1 | CD20-directed Cytolytic Antibody [EPC] | 252 |
| 2 | Interleukin-17A Antagonist [EPC] | 247 |
| 3 | Acetylcholine Release Inhibitor [EPC] | 192 |
| 4 | Neuromuscular Blocker [EPC] | 192 |
| 5 | Tumor Necrosis Factor Blocker [EPC] | 184 |
| 6 | Selective T Cell Costimulation Modulator [EPC] | 183 |
| 7 | Integrin Receptor Antagonist [EPC] | 168 |
| 8 | Insulin Analog [EPC] | 162 |
| 9 | Interleukin-6 Receptor Antagonist [EPC] | 140 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Selectin Blocker [EPC] | 22 | 0.0157 |
| 1 | Endoglycosidase [EPC] | 26 | 0.0140 |
| 2 | Interleukin-5 Antagonist [EPC] | 8 | 0.0116 |
| 3 | Interferon alfa-2b [EPC] | 21 | 0.0113 |
| 4 | CD30-directed Immunoconjugate [EPC] | 94 | 0.0090 |
| 5 | Interleukin-17A Antagonist [EPC] | 247 | 0.0066 |
| 6 | Skin Test Antigen [EPC] | 11 | 0.0058 |
| 7 | Cannabinoid [EPC] | 46 | 0.0057 |
| 8 | Guanylate Cyclase-C Agonist [EPC] | 10 | 0.0048 |
| 9 | Thymic Stromal Lymphopoietin Blocker [EPC] | 28 | 0.0040 |